Abstract
Overview
Introduction
There is a positive outlook for the respiratory market over the next five years, which will
experience a sustained period of growth driven by the expansion of sales in existing classes, the
launch of major new products, and the results from several landmark studies. However, the patent
expiries of two leading products, Singulair and Seretide, will see growth flatten from the turn of
the decade.
Scope
- Indication based forecasts for asthma/COPD products, with additional coverage of
antileukotrienes sales in allergic rhinitis
- Assessment of country-specific drivers and resistors likely to impact the market
- Future market outlook for individual products taking into account key market events in
particular, patent expiries, and competitor launches
- Market overview by geographical area, with value analysis of clinical and commercial factors
underlying product performance
Highlights
Global asthma/COPD sales should grow to $23 billion by 2014, with inhaled corticosteroid/long-acting
bronchodilator combinations set to be the leading class by value in 2014, followed by leukotriene
antagonists, and anticholinergics. AstraZenecas Symbicort should become the top-selling brand in
the global market, driven by the approval of Symbicort Maintenance and Reliever therapy (SMART) in
the EU, the launch of Symbicort in the US market, and the impact of generic competition on Advair/Seretide
sales. Four new launches are expected within the next five years, the most significant being
Symbicort in the US and the launch of novel ICS/LABA combination products which will need a strong
differentiation profile, based on improved safety, flexible dosing, or once-daily dosing to compete
with Advair/Seretide and Symbicort.
Reasons to Purchase
- Identify key environmental opportunities and threats that will impact the use and uptake of new
and existing products
- Quantify the future size and scope of the asthma/COPD market and predict the future performance
of key compounds
- Capitalize on clinical unmet needs in the market, either through the lifecycle management of
marketed drugs or new product development
| 
View Cart
